Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of trastuzumab + pertuzumab + docetaxel in HER2-mutated NSCLC
2018-003506-11Phase 2Completed
- Sponsor
- IFCT
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Overall response. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003506-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003506-11.